UBS Group AG Has $110.05 Million Stock Position in United Therapeutics Corporation $UTHR

Key Points

• UBS Group AG boosted its stake in United Therapeutics by 45.3% in Q4, adding 70,445 shares to hold 225,849 shares worth roughly $110.05 million (about 0.52% of the company).
• Analysts have lifted multiple price targets and the stock carries a consensus rating of "Moderate Buy" with a consensus target of $601.50 (ten Buys, three Holds).
• Insiders sold a substantial amount last quarter—469,205 shares worth about $253.9 million (including sales by the CFO and a director)—though insiders still own 10.30% of the company.

UBS Group AG lifted its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 45.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 225,849 shares of the biotechnology company's stock after acquiring an additional 70,445 shares during the quarter. UBS Group AG owned approximately 0.52% of United Therapeutics worth $110,045,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Clearstead Advisors LLC increased its position in shares of United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company's stock valued at $117,000 after acquiring an additional 23 shares during the last quarter. Bessemer Group Inc. grew its holdings in United Therapeutics by 2.6% during the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company's stock worth $472,000 after purchasing an additional 28 shares during the period. Archer Investment Corp grew its holdings in United Therapeutics by 9.5% during the third quarter. Archer Investment Corp now owns 356 shares of the biotechnology company's stock worth $149,000 after purchasing an additional 31 shares during the period. Signaturefd LLC grew its holdings in United Therapeutics by 4.1% during the fourth quarter. Signaturefd LLC now owns 896 shares of the biotechnology company's stock worth $437,000 after purchasing an additional 35 shares during the period. Finally, WealthCollab LLC grew its holdings in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. HC Wainwright lifted their price target on United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a report on Tuesday, March 31st. Cantor Fitzgerald lifted their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an "overweight" rating in a report on Thursday, March 12th. Morgan Stanley lifted their price target on United Therapeutics from $471.00 to $519.00 and gave the stock an "equal weight" rating in a report on Friday, April 10th. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, February 26th. Finally, Royal Bank Of Canada lifted their price target on United Therapeutics from $587.00 to $643.00 and gave the stock an "outperform" rating in a report on Thursday, February 26th. Ten analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $601.50.

United Therapeutics Stock Down 0.2%

Shares of NASDAQ:UTHR opened at $570.40 on Friday. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $607.89. The stock has a market cap of $25.00 billion, a PE ratio of 20.44, a P/E/G ratio of 1.63 and a beta of 0.75. The business has a 50 day moving average of $543.83 and a 200-day moving average of $497.42.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million during the quarter, compared to analysts' expectations of $814.80 million. During the same quarter in the previous year, the company posted $6.19 earnings per share. The business's revenue was up 7.4% on a year-over-year basis. Equities research analysts expect that United Therapeutics Corporation will post 27.97 earnings per share for the current year.

Insider Transactions at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $572.61, for a total transaction of $5,726,100.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,808,586.36. The trade was a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Christopher Patusky sold 2,910 shares of the business's stock in a transaction that occurred on Friday, April 24th. The stock was sold at an average price of $569.00, for a total value of $1,655,790.00. Following the sale, the director owned 1,490 shares of the company's stock, valued at approximately $847,810. This represents a 66.14% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 469,205 shares of company stock worth $253,860,521 over the last quarter. Company insiders own 10.30% of the company's stock.

United Therapeutics Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.